Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

S&P Biotech SPDR (XBI)

S&P Biotech SPDR (XBI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Price/Earnings ttm 17.88
  • Annual Dividend & Yield 0.14 (0.14%)
  • Most Recent Dividend 0.015 on 09/23/24
  • Management Fee 0.35%
  • Sectors:

    ETFs - Biotech

Options Overview Details

View History
  • Implied Volatility 24.94% ( +1.18%)
  • Historical Volatility 21.12%
  • IV Percentile 8%
  • IV Rank 12.89%
  • IV High 38.19% on 08/05/24
  • IV Low 22.98% on 11/12/24
  • Put/Call Vol Ratio 1.96
  • Today's Volume 164,603
  • Volume Avg (30-Day) 59,487
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 954,707
  • Open Int (30-Day) 866,873

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.11 +0.89%
on 10/23/24
105.47 -8.07%
on 11/11/24
-2.11 (-2.13%)
since 10/14/24
3-Month
95.08 +1.98%
on 10/10/24
105.47 -8.07%
on 11/11/24
+0.87 (+0.91%)
since 08/14/24
52-Week
69.32 +39.87%
on 11/16/23
105.47 -8.07%
on 11/11/24
+26.05 (+36.74%)
since 11/14/23

Most Recent Stories

More News
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 6.97 (-5.94%)
LLY : 786.23 (-3.15%)
INMB : 5.44 (-4.90%)
XBI : 96.96 (-3.05%)
BIIB : 164.89 (-0.54%)
SAVA : 26.14 (+3.81%)
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

ALDX : 4.27 (-3.17%)
STIM : 0.7900 (+29.59%)
PGY : 9.47 (-6.97%)
QSI : 0.7793 (-1.52%)
MNOV : 1.83 (-8.75%)
AXSM : 97.37 (-0.47%)
VSAT : 7.73 (-2.15%)
ZS : 208.50 (-0.64%)
BTM : 2.43 (-2.02%)
RVPH : 1.2100 (-3.20%)
SPY : 593.35 (-0.64%)
XBI : 96.96 (-3.05%)
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?

Moderna has underperformed the broader market and its peers over the past year, and Wall Street analysts are cautious about the stock’s prospects.

$SPX : 5,949.17 (-0.60%)
MRNA : 39.77 (-5.62%)
XBI : 96.96 (-3.05%)
Altimmune Stock Goes Parabolic Following Q3 Results As CEO Touts 2025 As ‘Transformational Year:’ Retail Upbeat

Altimmune is betting big on its investigational metabolic diseases candidate pemvidutide.

ALT : 8.45 (-11.24%)
XBI : 96.96 (-3.05%)
IWM : 231.94 (-1.35%)
Novavax Stock Slides As 2024 Revenue Cut Offsets Q3 Beat, Dampening Retail Confidence

Novavax CEO John Jacobs said the biopharma is looking to expand beyond COVID-19 and influenza.

NVAX : 7.22 (-7.02%)
IWM : 231.94 (-1.35%)
XBI : 96.96 (-3.05%)
Altimmune Stock Slides After New CFO Appointment, Retail Bulls Eye M&A Potential

The new hire’s background includes CFO roles at several biotech firms acquired in high-profile deals, such as Sirna Therapeutics (acquired by Merck) and ILEX Oncology (acquired by Genzyme).

IWO : 299.60 (-1.74%)
ALT : 8.45 (-11.24%)
IWM : 231.94 (-1.35%)
XBI : 96.96 (-3.05%)
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help biotechs by prompting accelerated drug approvals.

SRNE : 0.0038 (+2.70%)
TNXP : 0.1400 (-0.85%)
IBB : 140.09 (-2.58%)
JAGX : 1.0400 (+5.31%)
NVAX : 7.22 (-7.02%)
INO : 4.77 (-3.64%)
GILD : 92.11 (-0.56%)
MRNA : 39.77 (-5.62%)
VXRT : 0.6300 (-11.80%)
IBIO : 2.15 (-7.33%)
XBI : 96.96 (-3.05%)
PFE : 26.02 (-2.62%)
Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong

Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10.

IWC : 131.28 (-1.60%)
EBS : 9.27 (-7.02%)
VTI : 294.04 (-0.74%)
XBI : 96.96 (-3.05%)
Altimmune Stock Jumps As Obesity Drug Candidate Clears Key FDA Meeting: Retail Bulls Charge In

Altimmune said its obesity drug candidate is highly differentiated from other incretin-based agents currently available and in development.

IBB : 140.09 (-2.58%)
ALT : 8.45 (-11.24%)
XBI : 96.96 (-3.05%)
Moderna Stuns Wall Street With Surprise Profit On Strong US Vaccine Sales, Cost Tightening

Moderna attributed its strong third-quarter top-line growth to higher U.S. sales due to the earlier launch of the updated COVID-19 vaccine

IBB : 140.09 (-2.58%)
MRNA : 39.77 (-5.62%)
SPY : 593.35 (-0.64%)
XBI : 96.96 (-3.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Fund Summary

The SPDR SP Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the SP Biotechnology Select Industry Index.

See More

Key Turning Points

3rd Resistance Point 102.43
2nd Resistance Point 101.30
1st Resistance Point 99.13
Last Price 96.96
1st Support Level 95.83
2nd Support Level 94.70
3rd Support Level 92.53

See More

52-Week High 105.47
Last Price 96.96
Fibonacci 61.8% 91.66
Fibonacci 50% 87.40
Fibonacci 38.2% 83.13
52-Week Low 69.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar